Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 8/20 | 0.85 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.85 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.75 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.74 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.74 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.74 |
| ▸ | CES2 | O00748 | 1/20 | 0.74 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.71 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | SELP | P16109 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555867 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL3817083 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL235478 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL7700077 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL173282 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL15328013 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL15328011 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL7698286 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL17549876 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL30555910 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094669-A | Nucleic acid delivery compositions | — | 2026-05-26 | — | — | CN | claimed |
| EP-4734964-A1 | LIPID PARTICLES FOR DELIVERING A PAYLOAD | Repertoire Immune Medicines, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | claimed |
| CN-121586573-A | Lipopolymers for intra-articular administration | 伯尔尼大学 | 2026-02-27 | — | — | CN | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | claimed |
| US-20260028323-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | RINUAGENE BIOTECHNOLOGY CO., LTD. (CN) | 2026-01-29 | — | — | US | claimed |
| US-20260014075-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME | ST PHARM CO LTD (KR) | 2026-01-15 | — | — | US | claimed |
| US-20260000624-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE DISULFIDE BOND AND LIPID NANOPARTICLES COMPRISING SAME | ST PHARM CO LTD (KR) | 2026-01-01 | — | — | US | claimed |
| EP-1855595-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS | ID Biomedical Corporation of Quebec c.o.b. as Glaxosmithkline Biologicals North America (CA) | 2007-11-21 | — | — | EP | claimed |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| US-20070014841-A1 | Pharmaceutical compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| WO-2006096701-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2006-09-14 | — | — | WO | claimed |
| EP-1536831-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID Biomedical Corporation (CA) | 2005-06-08 | — | — | EP | claimed |
| US-20040132652-A1 | Pharmaceutical compositions | SHIRE BIOCHEM INC. (CA) | 2004-07-08 | — | — | US | claimed |
| US-20040062718-A1 | Particles for inhalation having sustained release properties | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-04-01 | — | — | US | claimed |
| WO-2004019976-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID BIOMEDICAL CORPORATION (CA) | 2004-03-11 | — | — | WO | claimed |
| US-20030026831-A1 | Anionic liposomes for delivery of bioactive agents | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | claimed |
| US-20020052310-A1 | Particles for inhalation having sustained release properties | MASSACHUSETTS INSTITUTE OF TECHNOLOGY THE PENN STATE RESEARCH FOUNDATION | 2002-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040062718-A1 | Particles for inhalation having sustained release properties | SMPD4, SMPD2, SMPD3 | LPAR1 112/4885ENPP2 102/4885LPAR3 88/4885 |
| US-20260000624-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE DISULFIDE BOND AND LIPID NANOPARTICLES COMPRISING SAME | SGMS1, SGMS2, NSUN3 | LPAR1 152/4885ENPP2 3538/4885LPAR3 174/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | LPAR1 140/4885ENPP2 265/4885LPAR3 441/4885 |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | NGLY1, PHOSPHO1, LPXN | LPAR1 217/4885ENPP2 38/4885LPAR3 297/4885 |
| US-20260014075-A1 | IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME | LDLR, CETP, NPC1 | LPAR1 34/4885ENPP2 1955/4885LPAR3 52/4885 |
| US-20020052310-A1 | Particles for inhalation having sustained release properties | SMPD4, SMPD2, SMPD3 | LPAR1 112/4885ENPP2 102/4885LPAR3 88/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | LPAR1 134/4885ENPP2 902/4885LPAR3 500/4885 |
| US-20260028323-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | NPC1, NPC1L1, SGMS1 | LPAR1 4/4885ENPP2 780/4885LPAR3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.